Recently, we found that activation of pDCs mediates the development of murine AIP and human AIP/IgG4-RD via the production of IFN-I and interleukin-33(IL-33) (17, 19–23). This evidence concerns the gene IL33 and immunoglobulin G4-related sclerosing disease.